Research progress on precision targeted therapy strategies for breast cancer based on tumor microenvironment.

Yunbo Luo, Panlin Xie, Shaokang Yang, Peng Qu, Lingmi Hou, Qun Yi

Abstract readReview

In one paragraph

Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yunbo LuoDepartment of Breast Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, Sichuan Province, China.

Panlin XieDepartment of General Internal Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

Shaokang YangDepartment of Critical Care Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.

Peng QuSchool of Laboratory Medicine, North Sichuan Medical College, Nanchong 637000, China.

Lingmi HouDepartment of Breast Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, Sichuan Province, China.

Qun YiDepartment of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tumor microenvironment (TME) plays a crucial role in the progression of BC, characterized by abnormal pH, aberrant enzyme expression, redox imbalance, etc. Nano-drug delivery systems (NDDSs) responsive to TME have emerged, including pH-responsive, enzyme-responsive, redox-responsive, and multi-responsive intelligent cascading systems. These systems effectively address tumor heterogeneity by improving intratumoral drug distribution and penetration, thereby enhancing therapeutic specificity and safety. In the future, the development of multi-modal intelligent NDDS, the design of programmable responsive systems, AI-driven personalized nano-drugs, and interdisciplinary collaboration to promote clinical translation will become key research focuses. This review not only systematically elucidates the response mechanism characteristics of TME in BC, but also focuses on analyzing the special requirements of the unique extracellular matrix and subtype specificity of BC for nanomedicine design. Furthermore, it summarizes the development directions of TME-responsive nano-delivery systems for BC, providing new insights to enhance the precise targeted therapy of BC.

Indexed as

cancermicroenvironmenttherapeutics

Identifiers

PMID42181279

DOI10.1016/j.isci.2026.116000

PMCPMC13197644

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.